Study S001183

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04904913
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 328
Start: 2021-06-08
Primary completion: 2023-03-29
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Overweight/ Obesity
Interventions: DRUG:IBI362; OTHER:placebo
Results posted: FALSE

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline ,week 24]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003407	Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial. Ji L, Med (New York, N.Y.)	2026	Randomized trial	PMID 41875890 DOI	cites ClinicalTrials.gov:NCT04904913; registry reference DERIVED:41875890
R0039583	1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more HONGWEI JIANG, Diabetes	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04904913
R0016107	A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Ji L, Nature communications	2023	Randomized trial	PMID 38092790 DOI	cites ClinicalTrials.gov:NCT04904913; registry reference DERIVED:38092790